Physician profile
Subhash Goyal
NPI 1184843021
$1,832.35
in general payments reported to CMS, 2019-2025
18 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $34.45 · 2021: $23.27 · 2023: $555 · 2024: $360 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.61 | 2019-2025 | Jardiance |
| Genzyme Corporation | $280.85 | 2023-2024 | |
| Amgen INC. | $237.69 | 2019-2024 | Prolia, Evenity, Repatha |
| Gilead Sciences, INC. | $144.92 | 2023-2025 | Livdelzi, Vemlidy |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Arexvy |
| Abbvie INC. | $99.75 | 2019-2024 | |
| Boston Scientific Corporation | $78.05 | 2023 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $78.01 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $74.80 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $72.86 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $70.13 | 2019-2020 | |
| Lilly USA, LLC | $41.27 | 2019 | |
| Pfizer INC. | $39.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.46 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.55 | 2024 | |
| Exact Sciences Corporation | $32.90 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $24.24 | 2024 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.